InterMune, Inc. (ITMN) Reports Fourth Quarter and Full Year 2012 Financial Results and Business Highlights
2/22/2013 7:19:18 AM
BRISBANE, Calif., Feb. 21, 2013 -- /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced results from operations for the fourth quarter and full year ended December 31, 2012.
InterMune reported Esbriet® (pirfenidone) net revenue in the fourth quarter of 2012 of $8.2 million, compared with $2.7 million in the fourth quarter of 2011. Esbriet is InterMune's product marketed in Europe for adults with mild-to-moderate idiopathic pulmonary fibrosis (IPF), a chronic and ultimately fatal disease of the lungs.